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The gram-negative bacterium Francisella tularensis (Ft) is both a potential biological
weapon and a naturally occurring microbe that survives in arthropods, fresh water
amoeba, and mammals with distinct phenotypes in various environments. Previously,
we used a number of measurements to characterize Ft grown in Brain-Heart Infusion
(BHI) broth as (1) more similar to infection-derived bacteria, and (2) slightly more
virulent in naïve animals, compared to Ft grown in Mueller Hinton Broth (MHB). In
these studies we observed that the free amino acids in MHB repress expression
of select Ft virulence factors by an unknown mechanism. Here, we tested the
hypotheses that Ft grown in BHI (BHI-Ft) accurately displays a full protein composition
more similar to that reported for infection-derived Ft and that this similarity would
make BHI-Ft more susceptible to pre-existing, vaccine-induced immunity than MHB-
Ft. We performed comprehensive proteomic analysis of Ft grown in MHB, BHI,
and BHI supplemented with casamino acids (BCA) and compared our findings to
published “omics” data derived from Ft grown in vivo. Based on the abundance
of ∼1,000 proteins, the fingerprint of BHI-Ft is one of nutrient-deprived bacteria
that—through induction of a stringent-starvation-like response—have induced the
FevR regulon for expression of the bacterium’s virulence factors, immuno-dominant
antigens, and surface-carbohydrate synthases. To test the notion that increased
abundance of dominant antigens expressed by BHI-Ft would render these bacteria
more susceptible to pre-existing, vaccine-induced immunity, we employed a
battery of LVS-vaccination and S4-challenge protocols using MHB- and BHI-grown
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Ft S4. Contrary to our hypothesis, these experiments reveal that LVS-immunization
provides a barrier to infection that is significantly more effective against an MHB-S4
challenge than a BHI-S4 challenge. The differences in apparent virulence to immunized
mice are profoundly greater than those observed with primary infection of naïve mice.
Our findings suggest that tularemia vaccination studies should be critically evaluated in
regard to the growth conditions of the challenge agent.
Keywords: tularemia immunization, bacterial adaptation, virulence factor, bacterial capsules, bacterial media
INTRODUCTION
Francisella tularensis (Ft) is an extremely infectious gram-
negative bacterium that is readily aerosolized. Inhalation of
this select agent can lead to pulmonary tularemia which has a
mortality rate of ∼35% in the absence of treatment. Reportedly,
antibiotic-resistant strains of this bacterium were developed
by at least one nation’s biological weapons program (Oyston
et al., 2004). The risk of such an agent being maliciously
employed, in concert with the current lack of a licensed tularemia
vaccine, has prompted intense interest in Ft. This pathogen is
naturally-occurring in diverse environments including warm-
and cold-blooded hosts (Oyston et al., 2004) and has both
intracellular (replicative) and extracellular (transmissive) phases
(Abd et al., 2003; Forestal et al., 2007; Yu et al., 2007; Bar-
Haim et al., 2008; Thelaus et al., 2009). Mounting evidence
indicates that as Ft progresses through the intracellular cycle
(phagocytosis, phagosomal escape, logarithmic cytoplasmic
replication, induction of autophagic vacuoles, and cellular egress)
the bacterium adapts by modulating expression of many Ft genes
(de Bruin et al., 2007; Chong et al., 2008; Wehrly et al., 2009).
A number of studies have examined the role of relevant
environmental cues such as temperature (Horzempa et al., 2008),
iron (Deng et al., 2006; Lenco et al., 2007), and amino acid
concentration (Hazlett et al., 2008; Zarrella et al., 2011) on
bacterial gene expression. Horzempa et al. found that ∼11%
of the Ft transcriptome was differentially-expressed in Ft LVS
grown at 26 and 37◦C in Chamberlain’s defined medium
(CDM; Chamberlain, 1965; Horzempa et al., 2008). These genes
included heat-shock proteins and those involved in amino-acid
metabolism but, with one exception, did not include members of
the Francisella Pathogenicity Island (FPI) which are required for
infection of both mammalian and non-mammalian hosts. Deng
et al. compared Ft LVS grown in Mueller-Hinton Broth (MHB)
that was iron-replete or -deficient and identified 80 Fe-responsive
genes (Deng et al., 2006). The most strongly induced (10–20 fold
change) genes were those involved with synthesis and utilization
of Fe-chelating siderophores (Deng et al., 2006; Sullivan et al.,
2006; Ramakrishnan et al., 2008). In this study, more modest
impacts (∼2- to 3-fold) were noted for the remaining 75 genes
including chaperones, ribosomal proteins, and select FPI proteins
such as members of the Intracellular growth locus (Igl). Within
the mammalian environment, the bacterium is thought to be
exposed to fluctuations in growth phase and levels of nutrients
such as amino acids which are ∼20 times higher in the host
cell cytoplasm than in the extracellular milieu (Bergstrom et al.,
1974). Guina et al. observed that F. novicida (Fn) mutants
lacking a key transcriptional regulator (MglA) have a marked
survival defect upon entering stationary phase in a restrictive
environment (MHB). In this study, the defects were linked
to increased susceptibility to nutrient starvation and oxidative
stress (Guina et al., 2007). The impact of stationary phase on
the proteome of Ft has been confirmed with both the live
vaccine strain (LVS) and the human-virulent strain SchuS4 (S4)
(Lenco et al., 2009). Interestingly, FPI-induction in CDM-grown,
stationary phase LVS and S4 is lower (∼2-fold) than that reported
for Ft LVS and S4 grown in vivo which show an FPI-induction
of ∼4- to 5-fold (Twine et al., 2006a; Wehrly et al., 2009; Bent
et al., 2013; Thomas-Charles et al., 2013). We have used growth
of Ft LVS and S4 in MHB and BHI broth as FPI-restrictive and
FPI-permissive models respectively. By using BHI supplemented
with casamino acids (BCA) we found that Igl induction in BHI-
Ft is sensitive to the concentration of free amino acids (Hazlett
et al., 2008).
The mutability of Ft presents a challenge to vaccine
development as the nature of the challenge inoculum (with
potentially distinct antigenic compositions) can vary widely.
Upon entering the mammalian environment, the surviving
inoculated bacteria will presumably adapt regardless of its prior
history (i.e., phenotype). However, the window of time required
for complete bacterial adaptation and the impact of this window
on infection and immunization outcomes is still a developing
field of inquiry. Cherwonogrodzky et al. first reported that the
virulence of Ft LVS for naïve mice could be increased by repeated
passage of the bacterium in CDM to promote accumulation
of capsular material (Cherwonogrodzky et al., 1994). Loegering
et al. demonstrated that Ft LVS passed through host cells were
less pro-inflammatory to uninfected macrophages (M8) and
more virulent in naïve mice than were non-host-adapted/MHB-
grown bacteria (Loegering et al., 2006). Using Ft grown in
BHI or MHB as models of host-adapted and non-host-adapted
bacteria respectively, we found that Ft LVS and S4 grown in
BHI produce/retain more capsular material. We found that this
capsular material hinders various immune effectors and shortens
the median survival time (MST) of naïve mice by 12–24 h
(Hazlett et al., 2008; Zarrella et al., 2011). Faith et al. used
an aerosol challenge model of naïve mice to assess the impact
of growth in MHB, CDM, and BHI on the aerosolization and
infectivity of Ft LVS. The authors found that growth in BHI
was associated with better bacterial survival during aerosolization
and a decreased LD99 (Faith et al., 2012). Collectively, the
above findings indicate that Ft infection of naïve animals can
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be impacted modestly by the immediate growth history of the
challenge agent. This is reminiscent of early work with another
zoonotic adaptable pathogen, Yersinia pestis (Yp), in which
inoculation of naïve mice with bacteria that were pre-adapted
to mammalian environmental temperature resulted in a shorter
MST (Rosenwald and Lincoln, 1966). This now is understood to
result from adaptive changes in (i) the structure of Yp LPS (to a
less inflammatory form) and (ii) regulated expression of virulence
factors such as the capsular F1 Ag (Rebeil et al., 2004; Montminy
et al., 2006).
While the impact of growth-media/adaptation status on Ft
infection of naïve animals is developing, the role of these factors
on tularemia vaccination is less well-explored. Recently, we
reported that the immune-stimulatory nature of MHB-Ft makes
inactivated forms of these bacteria better immunogens against
challenge with Ft LVS (Kumar et al., 2016). Hypothetically,
immunization outcomes could be also impacted by differential-
growth of the challenge agent, which could display altered
susceptibility to vaccine-induced immunity—at least until the
challenge agent adapts to the host environment. Examples of this
include subunit vaccines against zoonotic pathogens such as the
Decorin-binding protein A (DbpA) of Borrelia burgdorferi (Bb)
and the Ft outer membrane protein A (FopA). Immunization
with DbpA protects mice against infection with in vitro cultivated
Bb but not tick-transmitted Bb. This is due largely to the fact
that DbpA is expressed in vitro but not by tick-borne spirochetes
(Hagman et al., 2000; Blevins et al., 2008). Similarly, vaccination
with purified FopA can provide significant protection against
challenge with MHB-Ft LVS but not against challenge with either
Ft S4 (Hickey et al., 2011) or BHI-Ft LVS (Hickey, 2011). The
protective capacity of FopA immunization correlates with the
lower levels of capsule and increased binding of FopA-specific Ab
observed with MHB-Ft LVS (Hickey et al., 2011; Zarrella et al.,
2011).
Here we used a battery of proteomic and serological analyses
combined with immunization and challenge assays to further
explore the impact of Ft’s phenotypic mutability on tularemia
vaccine research. We tested the hypotheses that (i) Ft grown in
BHI (BHI-Ft) displays a full protein composition more similar
to that reported for infection-derived Ft and (ii) that this
similarity would make BHI-Ft more susceptible to pre-existing,
vaccine-induced immunity than MHB-Ft. Our findings indicate
that, compared to Ft grown in MHB, BHI-Ft has increased
proteomic similarity to host-adapted Ft and altered reactivity
with infection-derived sera from multiple species. Significantly,
in multiple experiments, with distinct immunization strategies,
we found that immunized mice are significantly more susceptible
to respiratory challenge with BHI-Ft S4 than to challenge with
MHB-Ft S4. In effect, BHI-Ft S4 appears more virulent to
immunized mice than does MHB-Ft S4 despite the fact that there
is little difference in virulence to naïve mice.
MATERIALS AND METHODS
Bacteria and Fractionation
The LVS strain of Ft was acquired from BEI (NR-646) and
was grown in vitro in MHB, BHI, or BHI supplemented with
casamino acids (BCA) as previously described (Hazlett et al.,
2008; Hickey et al., 2011; Zarrella et al., 2011). LVSmutant strains
used here have been described elsewhere (Su et al., 2007). Ft S4
was used within the CDC-certified A/BSL-3 facilities of Albany
Medical College, the University of Pittsburgh, and the Trudeau
Institute. Late-log phase Ft grown in MHB, BHI, or BCA were
harvested by centrifugation (8,000 × g, 15 min, 20◦C). Bacterial
pellets were resuspended in the appropriate fresh growth media,
transferred to pre-weighed Eppendorf tubes, pelleted as above
after which the transfer supernatant was aspirated. Pellet wet
weights were determined and used to estimate cell numbers
based upon the estimate of 1mg of wet weight = 5 × 108
bacteria. Cells were resuspended to 2.5× 107/µl (higher bacterial
concentrations promoted protein precipitation in subsequent
steps) in 20 mM Tris, pH 8.0 containing 100 mMNaCl, 20 µl/ml
protease inhibitor cocktail (Sigma, #P8849). After determining
the protein concentrations (DC protein assay, BioRad, Hercules,
CA), equilibrated bacterial suspensions were supplemented with
EDTA to 5 mM, lysozyme to 100 µg/ml, Benzonase (1 µl/ml,
Sigma), and Triton X-114 (Acros, NJ) to 1% from a 10%
stock in PBS. Following a 1 h incubation at room temperature
with periodic gentle agitation, a 1/20 vol. aliquot was saved as
the whole-cell (WC) fraction; the WC and remaining sample
were stored at −20◦C overnight. The samples were thawed
and incubated at RT until further viscosity reduction abated.
Following 15min incubation on ice, the samples were centrifuged
(20 min, 16,500 × g, 4◦C) to yield Triton X-114 soluble (TxS)
and insoluble (TxI) fractions. The TxS fractions were transferred
to fresh tubes and centrifuged again to remove any TxI carry-
over; the TxI fractions were washed twice with cold PBS (1
vol). The TxS fractions were incubated in a 32◦C water bath for
∼10 min followed by centrifugation (7,000 × g, RT, 15 min)
to effect phase partitioning (Bordier, 1981; Radolf et al., 1988;
Sjostedt et al., 1991; Hazlett et al., 2001, 2005) into aqueous
(top) and detergent (bottom) phases (any protein precipitation
at this step rendered the samples useless, such experiments were
discarded). Recovered phases were washed by supplementation
(to 1% Triton X-114—A or 10 vol PBS—D) followed by phase
separation; three washes per recovered phase were performed.
The washed Triton insoluble (TxI) phases were resuspended
in PBS containing 0.2% sarkosyl (Fisher Scientific, Fair Lawn,
NJ) and incubated for 20min with gentle agitation followed by
centrifugation (30min, 4◦C, 16,500 × g). The sarkosyl-soluble
(SS) fraction was recovered and centrifuged a second time
to remove any carryover of insoluble material. The sarkosyl-
insoluble (SI) material was washed once with PBS, 0.2% sarkosyl
and dissolved in 10mM Tris, pH = 8.0 containing 1% SDS.
WC, A, D, SS, and SI fractions were resolved by SDS-PAGE.
Occasionally the D, SS, and SI phases were pooled to represent
the total membrane fraction.
SDS-PAGE and Western Blot Analysis
Samples derived from 10 µg of Ft protein (∼1 × 108 cells)
were mixed with Laemmli sample buffer and boiled for 10 min
prior to resolution through 4–12% gradient SDS-PAGE pre-cast
gels (Invitrogen). The running buffer was NuPAGE MES SDS
buffer from Invitrogen; gels were variously run at 90–160 V.
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Resolved gels were stained with either Coomassie blue (BioRad)
or transferred to nitrocellulose membranes. Coomassie-stained
gels were scanned into Adobe Photoshop using an HP 2820
scanner. Membranes were blocked for 30 min with PBS, 0.05%
Tween 20, 5% non-fat dry milk. Primary Abs were applied
for overnight incubation at dilutions ranging from 1:1,000 to
1:60,000. Blots to be probed multiple times were first probed
with mAb prior to stripping and reprobing with polyclonal sera.
HRP-conjugated secondary Abs were used at dilutions ranging
from 1:1,000 to 1:20,000. Occasionally the secondary conjugate
was a biotinylated goat α-species-specific Ab followed by a
tertiary conjugate of streptavidin-linked HRP. Development of
the chemiluminescent substrate (SuperSignal West Pico, Pierce,
Rockford, IL) was visualized using an Alpha Innotech imaging
system in movie mode. Densitometric analysis of developed blots
was performed on the same system.
Proteomics
Sample Preparation for Mass Spectrometry
For each growth condition (MHB, BHI, or BCA), the WC and
4 subfractions (A, D, SS, SI) were run on SDS-PAGE gels either
Full-Length (WC and A), or in a Gel Plug (D, SS, SI). Each
fraction was mixed with sample buffer (w/β-ME) to a final vol of
100 µl. Full-Length: loaded 10 µl (1 × 108 Ft eq)/lane on 4–12%
SDS-PAGE gradient gels ran at 50 V for 4 h (Invitrogen). Gel-
Plug: loaded 10 µl (5 × 108 Ft eq)/lane on 12% SDS-PAGE gel
ran at 50 V for 40 min to create “1D-Gel plug” (Invitrogen). All
SDS-PAGE gels were stained with 25 mL Imperial Stain (Thermo
24615) for 1 h at 22◦C and destained overnight at 4◦C.
Trypsin Digestion of Samples from SDS-PAGE Gels
SDS-PAGE Gel Sectioning: Samples from full-length SDS-PAGE
gels (WC and A) were cut into 10 equal sections. Samples from
the D1 and SS gel-plug SDS-PAGE were cut into two equal
sections while the SI samples were cut into one section. Trypsin
Digestion: Protein bands to be analyzed, from SDS-PAGE gels,
were excised by sterile razor blade and chopped into ∼1 mm3
pieces. Each sample was washed in water and destained using
100 mM ammonium bicarbonate pH 7.5 in 50% acetonitrile.
A reduction step was performed by addition of 100 µl 50 mM
ammonium bicarbonate pH 7.5 and 10 µl of 10 mM Tris (2-
carboxyethyl) phosphine HCl at 37◦C for 30 min. Proteins were
alkylated by adding 100 µl 50 mM iodoacetamide and allowed to
react in the dark at 20◦C for 30 min. Gel samples were washed
in water, then acetonitrile, and dried in a SpeedVac. Trypsin
digestion was carried out overnight at 37◦C with 1:50 enzyme-
protein ratio of sequencing grade-modified trypsin (Promega)
in 50 mM ammonium bicarbonate pH 7.5, and 20 mM CaCl2.
Peptides were extracted with 5% formic acid and vacuum dried.
Isotopic Labeling
Peptide digests were reconstituted with 70 µl of Tris–HCl buffer
solution (10 mM Tris-HCl, 150 mM NaCl, 20 mM CaCl2, pH
7.6), vortexed for at least 20 min to reconstitute the peptide
mixture, then split into two vials of 30 µl each (16O vial and
18O vial), and 10 µl was retained unlabeled and stored in−80◦C.
In a separate vial, Mag-Trypsin beads (Clontech) were prepared
as follows. Thirty microliters mag-trypsin beads per rxn (16O
or 18O) were pooled and washed three times with 800 µl of
Tris–HCl buffer solution, then brought back up in 30 ul/sample
of Tris-HCl buffer, and aliquoted to a new 1.5 ml vial in the
quantity of 30 µl, vortexing lightly after each aliquot to keep
the mag-trypsin beads in suspension. Using a magnetic rack,
the Tris-HCl buffer was removed from the beads, and the 30
µl of sample digest from above was added to the beads and
vacuum dried. Thirty microliters of either 16O H2O or 97%
18O H2O (Cambridge Isotopes Laboratories) was added to the
respective 16O or 18O prepared Mag-Trypsin bead vial and
vortexed for 20 min to reconstitute the peptide mixture, and
allowed to exchange overnight at 37◦C. After 18O exchange, the
solution was transferred to a new vial and any free trypsin in
solution was inactivated with 1 mM PMSF for 30 min at 4◦C. For
each sample section, the digests were combined 1:1 as follows:
Forward (FWD) Sample Set: (BHI)-16O:(BCA)-18O, or (BHI)-
16O:(MHB)-18O. Reversed (REV) Sample Set: (BCA)-16O:(BHI)-
18O, or (MHB)-16O:(BHI)-18O. Samples were dried and stored at
−80◦Cuntil analysis. Three biological replicate experiments were
performed.
HPLC for Mass Spectrometry
The peptide samples were loaded to a 0.25 µl C8 OptiPak
trapping cartridge custom-packed with Michrom Magic C8
(Optimize Technologies), washed, then switched in-line with a
20 cm by 75 µm C18 packed spray tip nano column packed
with Michrom Magic C18AQ, for a 2-step gradient. Mobile
phase A was water/acetonitrile/formic acid (98/2/0.2) whereas
mobile phase B was acetonitrile/isopropanol/water/formic acid
(80/10/10/0.2). Using a flowrate of 350 nl/min, a 90 min, 2-step
LC gradient was run from 5 to 50% B over 60 min, followed by
50–95% B over the next 10 min, hold 10 min at 95% B, back to
starting conditions and re-equilibrated.
LC-MS/MS Analysis
The samples were analyzed via electrospray tandem mass
spectrometry (LC-MS/MS) on a Thermo LTQ Orbitrap XL,
using a 60,000 RP survey scan, m/z 375–1,950, with lockmasses,
followed by 10 LTQCID scans on doubly and triply charged-only
precursors between 375 and 1,500 Da. Ions selected for MS/MS
were placed on an exclusion list for 60 s.
Database Searching
Spectral Count Samples. Tandem mass spectra were extracted,
charge state deconvoluted and deisotoped by MS-Convert.exe
version 3.0.9490. All MS/MS samples were analyzed using
Mascot (Matrix Science, London, UK; version 2.3.02) and
X! Tandem [The GPM, thegpm.org; version CYCLONE
(2010.12.01.1)]. Mascot and X! Tandem were set up to search
uniprot_with_Isoforms_FRATH_07_2012.fasta (7/1/2012)
assuming the digestion enzyme trypsin. Mascot and X! Tandem
were searched with a fragment ion mass tolerance of 0.60 Da
and a parent ion tolerance of 20 PPM. Oxidation of methionine,
n-Formylation of the n-terminus and iodoacetamide derivative
of cysteine were specified in Mascot and X! Tandem as variable
modifications. 18O Quant Samples. All Isotopic ∗.raw Data files
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were analyzed with MaxQuant version 1.2.2, searching against
the uniprot_with_Isoforms_FRATH_07_2012.fasta database
using the following criteria: 18O heavy label was selected for
quantitation with a min of 1 high confidence peptide to assign
quantitation H/L ratio. Trypsin was selected as the protease
with max miss cleavage set to 2. Carbamiodomethyl (C) was
selected as a fixed modification. Variable modifications were
set to Oxidization (M), Formylation (n-term). Orbitrap mass
spectrometer was selected using an MS error of 20 ppm and a
MS/MS error of 0.5 Da. One percent FDR cutoff was selected for
peptide, protein, and site identifications.
Criteria for Protein Identification
Spectral Count Samples. Scaffold (version Scaffold_4.5.1,
Proteome Software Inc., Portland, OR) was used to validate
MS/MS based peptide and protein identifications. Peptide
identifications were accepted if they could be established at
>95.0% probability by the Peptide Prophet algorithm (Keller
et al., 2002) with Scaffold delta-mass correction. Protein
identifications were accepted if they could be established at
>99.0% probability and contained at least 1 identified peptide.
Protein probabilities were assigned by the Protein Prophet
algorithm (Nesvizhskii et al., 2003). Proteins that contained
similar peptides and could not be differentiated based on
MS/MS analysis alone were grouped to satisfy the principles of
parsimony. 18O Quant Samples. Ratios were reported based on
theMS level light and heavy peak areas determined byMaxQuant
and reported in the proteinGroups.txt file as heavy/light. Proteins
were removed from this results file if they were flagged by
MaxQuant as “Contaminants,” “Reverse,” or “Only identified by
site.” Complete three biological replicates were performed, with
each biological replicate split into two technical replicates [18O
forward (FWD) labeling, and 18O reverse (REV) labeling]. The
abundance data from each biological replicate were normalized
within Maxquant to the overall median peak intensity. Light and
heavy peak intensities were analyzed in each run to determine
protein hits that fell into the category of either (BHI-only hits
or BCA-only hits) or (BHI-only hits or MHB-only hits) and
retained if they confirmed to this state across all runs. In the case
of (BHI-only or BCA-only protein hits) or (BHI-only or MHB-
only protein hits), spectral counts can be used as a proxy for
abundance.
Proteomics Data Analysis and Presentation
Spectral Counting. For each biological replicate the total spectral
counts derived from 1 × 108 Ft (10 µg of protein) were used to
calculate the mean (± standard deviation) spectral counts (SC) as
a semi-quantitative proxy of protein abundance in each growth
condition. In each growth condition the proteins were ranked
by abundance with the protein having the highest mean spectral
counts listed as number one. We also normalized abundance to
a quasi-molar metric by dividing the mean spectral counts by
10 for each 10 kDa of mass for each protein; this was used in
recognition of the fact that large proteins generate more tryptic
peptides, and therefore spectral counts, than smaller proteins.
18O labeled-peptides. For each biological replicate tryptic peptides
were subject to duplicate technical analysis with reciprocal-
labeling to determine the mean FC for each biological replicate.
The data reported here is the mean FC and standard deviation
derived from the means of two to three biological replicates.
To determine which mean FCs were statistically significant we
performed a t-test of the mean FC compared to a FC = 1 (no
change) and p> 0.05 were considered significant.
Infection-Derived Immune Sera Used for
Western Blotting
S4-convalescent mouse serum. Six to eight week old C57BL/6
mice (Taconic, Germantown, NY) of either sex (n = 10) were
used for raising antisera against Ft S4. Mice were anesthetized
by intraperitoneal injection of a cocktail of Ketamine (5 mg/kg)
(Fort Dodge Animal Health, Fort Dodge, IA) and Xylazine (4
mg/kg) (Phoenix Scientific, St. Joseph) and checked for the loss of
toe-pinch reflex. Anesthetized mice were immunized intranasally
(i.n.) on day zero with 2 × 103 colony forming units (CFU)
of live, MHB-grown Ft LVS in 20 µl (10 µl/nare) of sterile
PBS. Identical booster immunizations were administered on
d14 and d28. On d42, the immunized mice were challenged
i.n. with 26 CFU of MHB-grown Ft S4. One hundred percent
of these mice survived. The same mice were challenged again
with 100 CFU of MHB-grown Ft S4 on d72; again all mice
survived. On d100, mice were re-challenged with 500 CFU of
MHB-grown Ft S4. On day 111, the surviving mice (100%)
were bled by retro orbital venipuncture; sera were harvested
and stored at −80◦C until further use. The immunization and
challenge doses were confirmed by plating serial dilutions on
MHB chocolate agar plates. The plates were incubated at 37◦C in
the presence of 5% CO2 for 48 h and the colonies were counted.
S4-convalescent rabbit sera. Rabbit sera used here was previously
generated (Reed et al., 2014) in New Zealand White rabbits by
scarification on day zero with BHI-grown aroD Ft S4 followed
by aerosol challenge on d28 with 50–500 LD50 of BHI-grown
WT Ft S4. Sera were harvested on d56. LVS-immunized, human
sera. The USAMRIID Special Immunization Program supplied
aliquots of previously-banked, pre- and post- LVS-immunization
sera from 10 sero-positive, de-identified study participants.
Provision and use of these human sera as described herein was
approved by the Institutional Review Boards of USAMRIID
and Albany Medical College. The Institutional Animal Care
and Use Committees (IACUCs) of Albany Medical College, the
University of Pittsburgh, and the Trudeau Institute approved
animal protocols used herein.
Murine Vaccination and Challenge
Four independent challenge experiments were conducted. In
the first two, conducted at Albany Medical College and the
University of Pittsburgh respectively and shown in Figure 4,
groups of female BALB/c mice (n= 6–8/group) were immunized
three times on d0, d14, and d28 with PBS or 200 CFU of
live Ft LVS. Mice were challenged on d42 with Ft S4 and
monitored for 14d. For the AMC trial, mice (Taconic) were
primed intradermally (i.d.) and boosted twice intranasally (i.n.)
with PBS or live, MHB-Ft LVS prior to i.n. challenge with 25
CFU of MHB-Ft S4. For the University of Pittsburgh trial, mice
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(Charles River) were primed i.n. and boosted twice i.n. with PBS
or BHI- Ft LVS prior to challenge with 34 CFU of BHI-Ft S4
delivered via aerosol. In the third experiment (Figure 5), two
groups (n = 20/group) of C57/BL6 mice (Taconic; ½ male, ½
female) were primed i.d. and twice boosted i.n. on d11 and d25
at AMC with either PBS or 200 CFU of live, MHB-Ft LVS. Mice
were challenged i.n. on d42 at the Trudeau Institute with 26 ±
2 CFU of either MHB- or BHI-Ft S4 and monitored for 21 d. In
our final experiment (Figure 6), two groups (n = 22–24/group)
of C57/BL6 mice (Taconic; ½ male, ½ female) were primed i.d.
and boosted i.n. once on d21 at AMC with either PBS or 1,000
CFU of live, BHI-Ft LVS. On d42 the mice were challenged i.n.
with 29.5 ± 2.5 CFU of Ft S4; half of each group was challenged
at AMC with MHB-Ft S4; the other half was challenged at the
Trudeau Institute with BHI-Ft S4. Survival was monitored for
21 d. The IACUCs of Albany Medical College, the University of
Pittsburgh, and the Trudeau Institute approved animal protocols
used herein. All challenge-survival data are presented as Kaplan–
Meier survival curves with statistical analysis by the Log-rank
(Mantel–Cox) test.
RESULTS
Previously, in an effort to identify in vitro cultivation conditions
for Ft that yielded “host-adapted”-like bacteria, we used a variety
of biochemical and immunological approaches to compare Ft
grown in MHB and BHI to Ft grown within macrophages
(M8s). Collectively our findings, based on ∼10 bacterial and/or
immunological parameters, suggested that BHI-Ft display a
phenotype similar to that of infection-derived Ft whereas the
phenotype of MHB-Ft is distinct (Hazlett et al., 2008; Zarrella
et al., 2011; Singh et al., 2013). To extend our understanding
of these phenotypes, here we performed a comprehensive
proteomics analysis of Ft LVS grown to late-log phase in broths of
MHB and BHI [without and with supplementation of casamino
acids (BCA)]. BCAwas included here as we previously found that
the addition of casamino acids to BHI down-regulates several Igl
proteins (Hazlett et al., 2008; Zarrella et al., 2011). We acquired
two types of LC-MS/MS data. The first was label-free, spectral
counting which provides a semi-quantitative measurement of a
protein’s abundance relative to other proteins in the same sample.
We also used 18/16O2 labeling which provides a highly accurate
fold change (FC) of a protein’s abundance between two distinct
samples. A comprehensive tally of our proteomics data, alongside
the published findings of others, is presented in Table S1.
Overview and Comparison with Existing
Datasets
We detected expression of 1,156 distinct Ft LVS proteins, 916 in
the 18/16O2 labeled samples and an additional 240 by label-free
detection. Our total detection rate of 67% of the hypothetical Ft
proteome is identical to that reported for a related quantitative
proteomics strategy recently used by Lenco et al. to interrogate
the proteomes of Ft LVS and Ft S4 (Lenco et al., 2009). Of the 845
proteins for which we have high-quality quantitative data, 17%
were more abundant [>1.5 FC that was statistically significant]
in BHI-Ft whereas 9% were less abundant (Table S1).
As the quality of our Ft data appeared to be comparable to
that of others, we next compared our BHI/MHB proteomics
FCs to existing “omics” FC datasets in which Ft grown in
mammalian cells and/or mice were compared to bacteria grown
in broth (Twine et al., 2006a; Wehrly et al., 2009; Bent et al.,
2013; Thomas-Charles et al., 2013). This comparison was possible
as FC is a form of data expression common to both “omics”
technics. Our goal was to very-broadly test the notion that BHI-
Ft is more similar, than MHB-Ft, to what has been reported
for host-adapted Ft. While comparing FCs across distinct
“omics” platforms and between different laboratories presents
some limitations, we perused this analysis with an eye toward
broad trends (operons, regulons, and protein families) that were
apparent in our data and within multiple reports for host-
adapted Ft. As a control, we also included the proteomics data
of Lenco et al. who analyzed Ft grown in vitro to stationary
and log phase in CDM (Lenco et al., 2009). Our BHI/MHB
FC dataset best fit the transcriptional datasets of Bent et al.
(FCs derived from Ft L Daygrown in M8s for 4 and 8 h vs.
in BCA) (Bent et al., 2013) and Thomas-Charles et al. (FCs
derived from Ft LVS grown in hepatocytes for 2 d vs. in MHB)
(Thomas-Charles et al., 2013). A linear regression analysis of
our data against the Bent et al. 4 h dataset revealed a very
low correlation (R2 = 0.04, Figure 1); the correlation between
our data and that of Lenco was moderately increased (R2 =
0.17). Our data showed the highest correlation with data derived
from 8 and 48 h of intracellular growth (R2 = 0.30 and 0.37
respectively); these latter two R2-values were not significantly
different from each other (correlation significance analysis,
http://vassarstats.net/). Collectively, these results suggest that
on a broad scale, BHI-Ft more closely reflect what has been
reported for bacteria that have grown in host cells for 8–
48 h.
Virulence Factors
Identifying the virulence factors (VF) of Ft has been a significant
area of interest for the tularemia field. Through the use of
mutant Ft and various infection models, a collection of the
bacterium’s VFs is emerging (Baron and Nano, 1998; Santic
et al., 2005, 2007; Brotcke et al., 2006; Tempel et al., 2006;
Su et al., 2007; Bonquist et al., 2008; Sammons-Jackson et al.,
2008; Barker et al., 2009; Buchan et al., 2009; Dean et al.,
2009; Schmerk et al., 2009; Ahlund et al., 2010; McCaffrey
et al., 2010; Broms et al., 2011, 2012a; Straskova et al., 2012;
Robertson et al., 2013, 2014) and currently contains 190
Francisella proteins. In our proteomics analysis, we detected
92% of these proteins which is significantly higher (p < 0.0002;
proportion analysis http://vassarstats.net/) than our overall Ft
protein detection rate (67%). Among these VFs, 26% were
up-regulated by 1.5-fold or more in BHI-Ft compared to
MHB-Ft; 9% were down-regulated in BHI (Table S1). The
percentage of BHI up-regulated VFs was significantly higher
(p = 0.013; proportion analysis http://vassarstats.net/) than the
percentage of BHI up-regulated proteins in the broader proteome
(17%).
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FIGURE 1 | Comparative omics. The fold changes (FC) for each of the 845
proteins we quantified in both BHI- and MHB-grown Ft were plotted against
the transcriptional FC for the same genes determined by Bent et al. (2013) at
4 h (white squares), 8 h (gray squares), and Thomas-Charles et al. (2013)
(black triangles). Four lines of best fit (least squares, best fit linear regression)
are shown for comparison of our data with that of Bent 4 h (R2 = 0.04), Bent
8 h (R2 = 0.30), Thomas-Charlie (R2 = 0.37), and Lenco et al. (2009) (R2 =
0.17, open circles solid black line). Values for VgrG (6.6—BHI/MHB;
8.1—Bent, 8 h; 4.3—Bent, 4 h; 3.4—Thomas Charles, 48 h; 2.4—Lenco) are
indicated by asterisks to facilitate interpretation of the data. MHB,
Mueller-Hinton Broth; BHI, Brain Heart Infusion Broth; M8, Macrophages;
BCA, BHI supplemented with Casamino Acids; CDM, Chamberlain’s Defined
Medium; Stat., Stationary Phase; Log, Logarithmic phase.
The most studied VFs of Ft include the 17 Francisella
Pathogenecity Island (FPI) proteins, which likely form a type-
6 secretion system for the delivery of Ft effector proteins into
target cells (de Bruin et al., 2007; Ludu et al., 2008; Broms et al.,
2009, 2012a,b; Clemens et al., 2015). As shown in Table 1 (and
Table S1), we detected all FPI proteins with the exception of the
135 kDa protein PdpD (FTT1715)—whose gene is truncated in
Ft LVS (Lenco et al., 2009). The average FC for the FPI proteins
(excluding IglF [high level of variation]) was 5.3 in BHI-Ft
relative to MHB-Ft. In general, our FPI data compares favorably
with that of Bent et al. and Thomas-Charles et al. particularly
for the later time points of intracellular (IC) growth (Table 1 and
Table S1). Similarly, our findings generally mirror those derived
from mouse and M8 models with Ft S4. Twine et al. purified Ft
S4 from murine spleens 4 d post-infection and used proteomics
to compare these to MHB-Ft (Twine et al., 2006a); Wehrley et al.
used transcriptional analysis to compare Ft S4 grown within
culturedM8s (for 1–24 h) to Ft S4 grown in CDM (Wehrly et al.,
2009). Based on the available Ft S4 data, the FPI expression we
observed with Ft LVS in BHI appears to echo S4 FPI induction
reported in Ft from mouse spleens (Twine et al., 2006a) and in
M8s at ∼12–16 h (Wehrly et al., 2009) (Table S1). To confirm
key findings of our proteomics data, we performed SDS-PAGE
and western blot analysis of MHB-, BHI-, and BCA-grown Ft
LVS along with BHI-grown Ft S4. As shown in Figure S1, BHI-
grown Ft contained elevated levels of VgrG (FTL0123/FTT1702),
IglC (FTL0113/FTT1712), and IglB (FTL0112/FTT1713). IglC
and IglB levels were comparable in BHI-grown LVS and S4 while
VgrG levels were slightly higher in S4 than LVS—as previously
reported (Lenco et al., 2009).
Regulation of Ft virulence is also an active area of investigation
with ∼15 Ft proteins identified as having various degrees
of influence on VF/FPI gene expression. The most well-
characterized of these are MglA (FTL1185) and SspA (FTL1606)
(homologs of the E. coli stringent starvation protein A—SspA),
and the DNA-binding protein FevR (FTL0449, also called PigR).
In the presence of ppGpp, FevR binds both to DNA up-
stream of VF promoters and to a protein complex including
MglA, SspA, and RNA polymerase to affect transcription of the
MglA/SspA/FevR regulon which contains many Ft VF genes—
including fevR andmost of the (Brotcke et al., 2006; Charity et al.,
2007, 2009; Brotcke andMonack, 2008; Rohlfing and Dove, 2014;
Ramsey et al., 2015). We observed a 5.0 FC for FevR in BHI-Ft
relative to MHB-Ft (Table 1 and Table S1)—values that closely
track the average FPI FC. Among the remaining FPI regulators,
we observed that PmrA (FTL0552) levels were slightly higher (FC
= 2.0, Table 1 and Table S1) in BHI-Ft as we previously reported
(Hazlett et al., 2008). Levels of SspA, OxyR (FTL1014), QscC
(FTL1762), TrmE (FTL1177), SpoT (FTL1413), Fur (FTL1831),
and Hfq (FTL0898) were unchanged, and levels of MglA, MglB
(FTL1184), MigR (FTL1542), and CphA (FTL0831) trended
lower in BHI-Ft (Table 1 and Table S1). The changes we observed
for the FPI regulators (particularly for FevR) in BHI-Ft appear to
mirror those reported for bacteria grown in host cells (Wehrly
et al., 2009; Bent et al., 2013) and are greater than that observed
for Ft grown to stationary phase in CDM (Lenco et al., 2009).
Generation of ppGpp to activate the FevR regulon is
dependent on RelA (FTL-0285) and/or SpoT activity (Charity
et al., 2009) and is inducible through amino acid starvation
experimentally-triggered by serine hydroxamate (Dean et al.,
2009; Faron et al., 2013). Under these conditions, ppGpp levels
rise by 2- to 3-fold and correspond with a 2- to 3-fold increase
in iglA promoter activity (Faron et al., 2013). By comparing the
proteomes of Ft grown in BHI and BCA [BHI supplemented with
casamino acids (the amino acid source in MHB)] we were able
to explore the extent to which amino acid starvation contributes
the differences in MHB- and BHI-grown Ft. Consistent with the
reported impact of serine hydroxamate, we found the absence
of casamino acids induced an average FPI protein induction of
2.2-fold and a 2.6 induction of FevR (Table 1). These values are
similar to those reported for Ft grown in M8 for 4 h (ave FPI-
2.2, FevR 3.2) but lower than the full FPI induction reported
for Ft grown in M8 for 8 h (ave-FPI 4.6, FevR 6.9) and what
we observed between BHI- and MHB- grown Ft (ave FPI-5.3,
FevR 5.0). These data suggest that while amino acid limitation
alone can induce the FevR regulon 2- to 3-fold, additional,
possibly nutritional, signals contribute to full FPI induction.
Classically, nutrient starvation and induction of the stringent
starvation response (mediated by RelA/SpoT and ppGpp) results
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TABLE 1 | A sub-set of our proteomics data.
Locus (LVS,
S4)
Protein (MW-kDa) Spectral counts Fold changes VF FevR
regulon
Times
reports as
an antigen%
Sol.
Abundance
Rank MHB, BHI
BHI/MHB BHI/BCA M8/BCA, Bent,
4 h, 8 h
1,191, 1,269 DnaK (69) 93 3, 3 0.7 ± 0.1 1.2 ± 0.1 1.0, 0.9 Y 7
1,714, 1,696 GroE (57) 96 1, 1 1.2 ± 0.0 1.2 ± 0.0 0.5, 0.6 Y 8
1,751, 137 EFTu (43) 92 4, 4 0.8 ± 0.2 0.6 ± 0.1 1.0, 0.5 5
1,328, 583 FopA (41) 16 31, 59 0.8 ± 0.2 0.8 ± 0.1 1.7, 1.5 Y 6
FPI PROTEINS
126, 1,699 PdpA (95) 92 263, 24 4.8 ± 1.1 1.8 ± 0.1 3.2, 6.9 Y Y 0
125, 1,700 PdpB (125) 35 175, 26 6.6 ± 5.4 1.9 ± 0.0 1.9, 4.9 Y 0
124, 1,701 IglE (14) 0 955, 772 3.7 2.7 ± 1.3 2.0, 6.2 Y 0
123, 1,702 VgrG (18) 99 546, 224 6.6 ± 2.1 2.3 ± 1.0 4.3, 8.1 Y 0
122, 1,703 IglF (65) 80 868, 435 11.9 ± 13 0.1 ± 0.2 2.4, 6.3 Y Y 0
121, 1,704 IglG (18) – ND, 910 ND 0.7 ± 1.0 3.0, 6.1 Y 0
120, 1,705 IglH (55) 91 400, 95 6.5 ± 3.6 1.9 ± 0.9 2.5, 4.4 Y Y 0
119, 1,706 DotU (25) 61 487, 308 3.7 ± 2.3 1.0 ± 0.9 2.2, 2.9 Y Y 0
118, 1,707 IglI (45) 81 305, 57 5.4 ± 2.1 2.8 ± 0.5 2.0, 3.0 Y Y 0
117, 1,708 IglJ (30) 87 914, 501 5.2 ± 2.4 2.3 ± 0.4 1.7, 3.0 Y Y 1
116, 1,709 PdpC (156) 80 117, 7 6.3 ± 3.9 2.8 ± 0.3 0.9, 2.2 Y Y 0
115, 1,710 Hcp (22) 82 971, 489 8.2 ± 3.9 2.0 ± 0.6 1.5, 2.4 0
114, 1,711 IglD (46) 90 328, 117 4.8 ± 0.8 1.3 ± 0.0 1.7, 4.0 Y Y 0
113, 1,712 IglC (23) 96 59, 19 4.0 ± 0.4 4.0 ± 1.8 2.0, 5.4 Y Y 2
112, 1,713 IglB (55) 82 23, 6 4.0 ± 1.0 1.7 ± 0.2 2.1, 3.7 Y Y 2
111, 1,714 IglA (21) 83 310, 61 4.4 ± 1.4 1.8 ± 0.3 2.5, 4.3 Y Y 0
NA, 1,715 PdpD, NA ND ND ND ND NA Y 0
FPI protein average* 5.3 2.2 2.2, 4.6
KNOWN FPI REGULATORS
449, 383 FevR (13) 83 951, 655 5.0 ± 0.3 2.6 ± 1.8 3.2, 6.9 Y Y 0
552, 1,557 PmrA (26) 99 144, 175 2.0 ± 0.9 0.8 ± 0.1 0.6, 0.8 Y Y 0
1,606, 458 SspA (24) 92 417, 399 0.8 ± 0.2 1.3 ± 0.1 0.6, 1.2 Y 0
1,185, 1,275 MglA (22) 100 522, 654 0.6 ± 0.3 0.9 ± 0.1 1.9, 0.4 Y 0
1,184, 1,276 MglB (15) - 836, 963 ND ND 1.6, 0.8 Y 0
NON-FPI MARKERS of GROWTH HISTORY
1,503, 720 Dgt (50) 100 599, 360 5.2 ± 0.3 1.7 ± 0.1 3.2, 5.3 0
673, 1,390 PanC (30) 95 492, 225 4.1 ± 0.7 1.4 ± 0.3 1.0, 1.1 Y 0
675, 1,388 PanG (27) 88 743, 317 3.5 ± 0.7 0.7 + 0.4 1.8, 2.9 Y 0
207, 296 Pcp (24) 91 315, 178 3.0 ± 1.1 1.7 ± 0.1 4.3, 5.2 Y Y 0
1,832, 29 FslA (74) 74 643, 295 5.5 ± 4.8 2.4 ± 0.3 3.0, 5.9 Y Y 0
1,834, 27 FslC (47) 89 856, 333 7.5 ± 3.1 0.9 ± 0.2 2.2, 3.4 Y 0
78, 1671 RibD (40) 100 449, 792 0.43 ± 0.0 0.11 ± 0.0 1.1, 1.0 <s/> 0
1,739, 149 MetK (42) 91 212, 542 0.35 ± 0.0 0.54 ± 0.2 0.6, 0.5 0
1,478, 1,317 GuaB (52) 100 12, 55 0.35 ± 0.0 0.37 ± 0.2 0.3, 0.7 Y 1
LPS/CAPSULE ENZYMES
606, 1,450 WbtM (39) 100 334, 300 2.1 ± 0.3 0.7 ± 0.1 0.9, 1.6 Y Y 0
600, 1,456 WbtH (72) 67 247, 242 1.7 ± 0.0 0.9 ± 0.3 0.3, 0.3 0
596, 1,460 WbtE (49) 98 74, 64 1.5 ± 0.1 1.0 ± 0.2 0.5, 0.5 Y 0
595, 1,461 WbtD (42) 94 476, 402 1.5 ± 0.2 0.6 ± 0.3 0.5, 0.5 Y Y 0
(Continued)
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TABLE 1 | Continued
Locus (LVS,
S4)
Protein (MW-kDa) Spectral counts Fold changes VF FevR
regulon
Times
reports as
an antigen%
Sol.
Abundance
Rank MHB, BHI
BHI/MHB BHI/BCA M8/BCA, Bent,
4 h, 8 h
1,399, 1,478 KdsB (28) 93 276, 238 1.8 ± 0.4 1.0 ± 0.0 1.2, 2.2 0
609, 1,447 ManB (55) 100 558, 585 1.6 ± 0.2 0.6 ± 0.6 0.8, 0.9 Y 0
RIBOSOMAL PROTEINS
47 ribosomal proteins for which we have matched data 24 down 8 down 12 down,
32 down
FTL (LVS) and FTT (S4) locus numbers are indicated along with the proteins name and mass predicted from the LVS genome. Data based upon label-free spectral counts include
solubility [the percentage of each protein’s total tryptic peptides detected in either the soluble (S) or membrane (M) fractions] and abundance rank for each protein in MHB-Ft and
BHI-Ft. Fold change data is based on reciprocal 16O and 18O labeling performed in biological duplicate to yield the indicated mean and standard deviations. Numerical data in bold font
represent statistically significant changes [for each protein the status as a virulence factor (VF) was drawn from (Baron and Nano, 1998; Lai et al., 2001; Santic et al., 2005; Brotcke et al.,
2006; Maier et al., 2006; Tempel et al., 2006; Maier et al., 2007; Santic et al., 2007; Su et al., 2007; Thomas et al., 2007; Bonquist et al., 2008; Sammons-Jackson et al., 2008; Barker
et al., 2009; Buchan et al., 2009; Dean et al., 2009; Schmerk et al., 2009; Ahlund et al., 2010; McCaffrey et al., 2010; Broms et al., 2011, 2012a; Straskova et al., 2012; Robertson
et al., 2013, 2014; Rasmussen et al., 2015)]; status as a FevR regulon member was drawn from Charity et al. (2007, 2009), Brotcke and Monack (2008), and Ramsey et al. (2015); the
number of times each protein has been reported as a target of infection-derived Ab was drawn from references (Twine et al., 2006b, 2010, 2012a; Janovska et al., 2007; Sundaresh
et al., 2007; Savitt et al., 2009; Fulton et al., 2011; Nuti et al., 2011; Golovliov et al., 2013; Chu et al., 2014), and the transcriptional fold changes upon intracellular growth for 4 and 8 h
were drawn from Bent et al. (2013). *Excludes values for IglF.
in decreased abundance of ribosomes. Of the 47 ribosomal
proteins for which we had robust FC data, 24 were statistically
less abundant in BHI-Ft compared toMHB-Ft (Table 1 and Table
S2) Among these 47 proteins, 8 were reduced in BHI compared to
BCA; 12 and 32 are reportedly reduced after 4 and 8 h respectively
of growth in M8. Thus in our data, as well as that of Bent for
LVS (Bent et al., 2013) and Lenco for LVS and S4 (Lenco et al.,
2009), FPI induction appears to correlate with ribosomal protein
reduction.
Collectively, the protein fingerprint of log-phase BHI-Ft
(compared to MHB Ft) is one of nutrient-depleted bacteria
that—through induction of a stringent starvation-like response—
have induced the FevR regulon for high-level expression of the
bacterium’s VFs.
LPS and Capsule Synthesis
Another category of Ft proteins that contribute
significantly to virulence are the ∼65 enzymes that
synthesize/modify/incorporate carbohydrates into the
bacterium’s surface-coating of polysaccharides. Principal
among these polysaccharides is the four sugar, O-antigen moiety
synthesized by the Wbt enzymes and incorporated into polymers
found in both the bacterium’s LPS and the discrete O-Ag capsule.
Previously, we demonstrated that BHI-Ft have higher molecular
weight capsular polysaccharides and longer polymers of LPS
O-Ag compared to MHB-Ft although the mechanistic basis
for this observation was unknown (Zarrella et al., 2011). In
our proteomics data (Table 1 and Table S1) for BHI-Ft, we
observe moderately increased levels of several Wbt enzymes
(M, H, E, and D) as well as KdsB and ManB—enzymes that
contribute to synthesis of the KDO core which links O-Ag
to Lipid A. Among the remaining ∼40 LPS/Capsule related
proteins (Lpx, Waa, Lpc, Lpt, Flm, and Nax members) for
which we have robust data, no significant differences were noted
between MHB-Ft and BHI-Ft (Table S1). As with many Ft
LPS/capsule synthases, perturbations of WbtM, WbtE, WbtD,
and ManB reduce the bacterium’s polysaccharide coat rendering
the pathogen highly susceptible to host defenses (Thomas et al.,
2007; Lai et al., 2010; Lindemann et al., 2011; Twine et al.,
2012b; Okan et al., 2013; Rasmussen et al., 2015). Currently, it
is unclear if the increased abundance of the Wbt, Kds, and Man
enzymes reported here for BHI-Ft is sufficient to account for
the increased surface polysaccharides we previously described.
Another potential factor, increased retention of capsular
material, has also been postulated for BHI-Ft (Faith et al., 2012)
and a mechanism of such retention, lipid-modification of O-Ag
capsule, has recently been reported for BHI-Ft (Barker et al.,
2016).
Immuno-Dominant Antigens
To date, 81 Francisella proteins have been reported one or more
times to be immunogenic in an immunization or sub-lethal
infection model (Twine et al., 2006b, 2010, 2012a; Janovska et al.,
2007; Sundaresh et al., 2007; Savitt et al., 2009; Fulton et al.,
2011; Nuti et al., 2011; Golovliov et al., 2013; Chu et al., 2014).
We detected 100% of these proteins, which is significantly (p <
0.0002) higher than our overall Ft protein detection rate (67%).
Among the immunogenic proteins, 18% were more abundant
in BHI-Ft while 13% were more abundant in MHB-Ft. In the
course of our analysis we made an intriguing observation—
the proteins most frequently reported to be immunogenic were
among those that we measured as the most abundant. For
example, in our label-free, spectral count data, GroEL (FTL1714)
and DnaK (FTL1194) were the 1st and 3rd most abundant
proteins in Ft (Table 1) and these proteins have been described
as immunogenic by nearly every group that has performed Ft
immunoproteomics. To further explore the relationship between
protein abundance and reports of immunogenicity, we plotted
the spectral counting abundance (normalized for protein size
as larger proteins generate more peptides) for >1,100 proteins
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FIGURE 2 | Ft protein abundance correlates with antibody reactivity. The
average normalized abundance of the 1,139 Ft proteins we detected (Y-axis)
was plotted against the number of times (0 to >3) that each protein has been
reported as Ab reactive with infection-derived sera (X-axis). X axis values in
parentheses indicate the number of Ft proteins with the indicated number of
reports of sero-reactivity (0 to >3). Means and standard deviations from two to
three biological replicates are indicated; statistical analysis was via 2-tailed,
heteroscedastic T-test with Bonferroni correction with four comparisons.
Indicated p-values are for the BHI dataset.
against the number of published reports of immunogenicity for
each protein. As shown in Figure 2 there is a strong linear
trend between a protein’s abundance and the likelihood that the
protein will have been reported as immunogenic. This trend
was similar whether we used data from BHI- or MHB-grown
Ft. The mean normalized abundance for the proteins in each
category (1 report up to >3 reports) was significantly higher
than the abundance of proteins that had not been reported as
immunogenic.
As several immunogenic proteins are also differentially
expressed to become highly abundant in BHI-Ft (Table 1), we
hypothesized that sera from S4-surviving subjects might react
differently with Ft that had been differentially cultivated. Inspired
by recent reports from the Bosio group (Griffin et al., 2015;
Roberts et al., 2016) indicating that C57BL/6 mice can be
successfully immunized against challenge with MHB-Ft S4, we
generated S4-convalescent mouse sera using live LVS in a prime-
boost-boost strategy followed by an increasing challenge-dose
regimen (26-100-500 CFU) with MHB-Ft S4. As a source of
outbred S4-convalescent Ab, we used rabbits that had been
primed with Ft S4 1aroD and challenged with BHI-Ft S4
prior to serum collection (Reed et al., 2014). For comparison,
we also used sera from another outbred population, LVS-
immunized humans. With these 3 sera, we probed by western
blot, whole cell (WC), soluble, and membrane fractions of
Ft LVS that had been grown in MHB, BHI, or BCA. As
shown in Figure 3, the outbred rabbit and human sera strongly
recognized the typical “ladder pattern” indicative of reactivity
with the LPS O-antigen (Ag). The ladder pattern was present
in the WC and membrane fractions of WT Ft LVS (Figure 3)
FIGURE 3 | Differentially expressed Ft proteins are immunogenic in multiple
models of infection. Whole cells (WC) lysates of Ft LVS grown in MHB (M), BHI
(B), or BCA (BC) were partitioned into soluble and membrane fractions prior to
SDS-PAGE (A) and western blot analysis (B–D). Each lane was loaded with
material derived from 1*10e8 Ft. Asterisks in (A) indicate 2 examples of
coomassie-visable, differentially-abundant proteins, one soluble ∼23 kDa and
one ∼120 kDa membrane. Replicate blots were independently probed with
sera from S4-convalescent, inbred (C57/BL/6) mice; a S4-convalescent,
outbred rabbit; and an LVS-vaccinated human. Asterisks in (B–D) indicate two
examples of differentially-detected moieties, one soluble ∼23 kDa and one
∼120 kDa membrane.
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FIGURE 4 | The outcome of tularemia vaccination trials can be influenced by
differential growth. Survival of BALB/c mice vaccinated three times with PBS
(squares) or live Ft LVS (triangles) prior to challenge with Ft S4. In (A) all Ft
were grown in MHB (open symbols); in (B), all Ft were grown in BHI (closed
symbols). Asterisks indicate significant differences between PBS- and
LVS-immunized groups that were identically-challenged. Actual challenge
doses were 25 CFU of MHB-Ft S4 (A) and 34 CFU BHI-Ft S4 (B). Actual p <
0.0001 (A) and p = 0.0001 (B). Median survival times (MTS) for
LVS-immunized mice were ≥ 14 d (A) and 12.5 d (B); for PBS-immunized
mice the corresponding values were 6.5 d (A) and 5 d (B). The survival data
from 30 mice used in two independent experiments with 6–8 mice/group are
represented as Kaplan–Meier survival curves with statistical analysis by the
Log-rank (Mantel–Cox) test.
and absent in preparations from O-Ag mutant Ft (data not
shown). In contrast, our hyper-immune Mo sera displayed
markedly reduced LPS-reactivity and instead showed prominent
reactivity with a discrete number of soluble and membrane
proteins (Figure 3); this pattern was unchanged when we probed
preparations from O-Ag deficient Ft (data not shown). A similar
discord between human and mouse immune serum reactivity
with Ft LPS has been noted previously by Huntley et al.
(2007).
Among the protein Ags recognized by these sera were
several differentially abundant species. In particular, all three
sera reacted with a soluble ∼ 23 kDa moiety present in
BHI-Ft at apparently higher levels than in MHB-Ft or
BCA-Ft (Figures 3B–D, soluble, asterisk). This pattern of
Ab-reactivity was mirrored by the abundance of a ∼23
kDa soluble protein visible on coomassie-stained SDS-PAGE
gels (Figure 3A) and by the reactivity with mAb against
FIGURE 5 | BHI-Ft S4 appears more virulent than MHB-Ft S4 to mice
immunized with MHB-LVS. Survival of C57BL/6 mice vaccinated three times
with PBS or live MHB-Ft LVS prior to i.n. challenge with 26 ± 2 CFU of Ft S4
grown in MHB or BHI. Symbols are as defined in Figure 4; survival differences
between immunized mice challenged with MHB-S4 and BHI-S4 are indicated
by the stated p-values. Asterisks indicate significant differences between
groups (PBS or LVS) that were identically-challenged; actual p valves are p <
0.0001 (MHB-S4) and p < 0.0001 (BHI-S4). All significant differences are
indicated. MTS values are ≥ 21 d (LVS/MHB-S4), 13 d (LVS/BHI-S4), 8.3 d
(PBS/MHB-S4), and 7.5 d (PBS/BHI-S4). The survival data from 40 mice (10
mice/group) are represented as Kaplan–Meier survival curves with statistical
analysis by the Log-rank (Mantel–Cox) test.
FIGURE 6 | BHI-Ft S4 appears more virulent than MHB-Ft S4 to mice
immunized with BHI-LVS. Survival of C57BL/6 mice vaccinated twice with
PBS or live BHI-Ft LVS prior to challenge with 29.5 ± 2.5 CFU of Ft S4 grown
in MHB or BHI. Symbols are as defined in Fig 4; survival differences between
immunized mice challenged with MHB-S4 and BHI-S4 are indicated by the
stated p values. Asterisks indicate significant differences between groups (PBS
or LVS) that were identically-challenged; actual p-values are p < 0.0001
(MHB-S4) and p < 0.017 (BHI-S4). All significant differences are indicated.
MTS values are >21 d (LVS/MHB-S4), 13.8 d (LVS/BHI-S4), 6 d
(PBS/MHB-S4), and 5.8 d (PBS/BHI-S4). The survival data from 46 mice
(10–12 mice/group) are represented as Kaplan–Meier survival curves with
statistical analysis by the Log-rank (Mantel–Cox) test.
IglC (Figure S2). Within the membrane fractions, the only
visible, differentially abundant Ag was a ∼120 kDa band
of reactivity in the outbred Rb and Hu sera (Figures 3C,D,
membrane, asterisks). The abundant O-Ag reactivity of these
sera may obscure additional differentially abundant membrane
species. Collectively, these results with sera from multiple
models and immunization schedules indicate that vaccine-
induced immunity recognizes several differentially-expressed Ft
Ags.
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Differential Growth of Ft S4 Governs the
Efficacy of Prophylactic Immunization
As several Ag differences inMHB-Ft and BHI-Ft were recognized
by immune/convalescent sera, we hypothesized that immunized
hosts might be differentially susceptible to challenge with these
two forms of the bacteria. Previously, we observed that naïve
mice infected with BHI-Ft (LVS or S4) showed a slightly
shorter median survival time (MST) compared to that of mice
challenged with MHB-Ft (Hazlett et al., 2008; Zarrella et al.,
2011). Here, we envisioned two distinct scenarios for immunized
mice challenged with Ft S4 previously grown in MHB or BHI.
The elevated reactivity of the differentially-expressed, dominant
Ags could render a challenge inoculum of BHI-Ft S4 more
susceptible to pre-existing immunity (which could result in
increased host survival). Alternatively, the thicker carbohydrate
coating, coupled to the immediate benefit of pre-formed VFs,
could make the BHI-Ft S4 challenge inoculum less susceptible
to pre-existing immunity (which should result in decreased host
survival).
Our first indication that the latter might be true came
inadvertently from independent vaccination trials. For both
trials, BALB/c mice were immunized using a prime-boost-boost
strategy in which live Ft LVS served as the positive control
for protection against challenge with Ft S4. In one case, the
Ft strains were grown in MHB; in the second case both Ft
strains were cultured in BHI. While LVS immunization provided
significant protection (p ≤ 0.0001) against S4 challenge in both
cases, protection for the MHB-based trial was absolute (100%)
but only partial (38% survival, 12.5 d MST) for the BHI-based
trial (Figure 4). The MST for control mice challenged with
MHB-Ft S4 was 6.5 vs. 5 d for those challenged with BHI-Ft
S4. While these results were intriguing, differences between the
independent trails necessitated further experimentation.
To assess more rigorously the impact of differential cultivation
on Ft vaccination, we set up a large-scale trial in which mice
vaccinated with liveMHB-Ft LVS in a prime-boost-boost strategy
were challenged with either MHB- or BHI-grown Ft S4. For these
experiments, we used C57BL/6 mice, which are harder to protect
against challenge with Ft S4 (Twine et al., 2012a), as a highly
stringent test of immunization efficacy. For LVS-immunized
mice, we again observed complete (100%) protection against
challenge with MHB-Ft S4 (Figure 5), which was significantly (p
= 0.007) higher than the survival observed for mice challenged
with BHI-Ft S4 (44% survival, 13 d MST). Survival of control
mice was not significantly different between the MHB-Ft S4
group (8.3 d MST) and the BHI-Ft S4 challenged group (7.5 d
MST). In the former experiment, the Ft LVS used for vaccination
had been grown in MHB raising the specter that survival among
the mice challenged with MHB-Ft S4 might have been the result
of a more specifically tailored, vaccine-induced immunity. To
test this notion, we assessed the ability of BHI-Ft LVS to protect
against challenge with MHB- and BHI-grown Ft S4. C57BL/6
mice were primed and boosted a single time with live BHI-Ft
LVS. Contrary to the notion of immunogen-tailoring, we again
observed that immunized mice survived challenge with MHB-
Ft S4 (70% survival, undefinable MST) significantly better (p =
0.038) than those challenged with BHI-Ft S4 (33% survival, 13.75
d MST) (Figure 6). Survival of PBS-immunized control mice
was not significantly different (p = 0.398) between the groups
challenged withMHB-Ft S4 (6 dMST) and those challenged with
BHI-Ft S4 (5.8 d MST).
Collectively, our vaccination studies demonstrate that
challenge with BHI-Ft S4 provides a more stringent test of
vaccine efficacy than challenge with MHB-Ft S4.
DISCUSSION
Several years ago we began characterizing broth- and M8-grown
Ft with the goal of identifying culture conditions that would
yield “host-adapted”-like bacteria. Our rationale was that these
Ft could be used with greater confidence in efforts to (i) identify
vaccine Ag candidates expressed during infection and/or (ii)
unravel details of the host-pathogen interaction that are operable
during infection. In previous studies, using a limited cadre of
∼10metrics that discernMHB-Ft fromM8- or mouse-grown Ft,
we concluded that Ft LVS and S4 grown in BHI roughly mimic
the phenotype of the mammalian, infection-derived pathogen
(Hazlett et al., 2008; Zarrella et al., 2011). Here we used ∼100-
fold more data to extend and further characterize the phenotypes
of MHB-, BHI-, and BCA- grown Ft. By comparing these FCs
to those previously reported for infection of cells or mice, we
can reasonably conclude that the differences observed between Ft
grown in MHB and BHI are most similar to that of LVS grown in
MHB (or BCA) and host cells for 8 and 48 h (R2 = 0.3 and 0.37).
These correlation coefficients are significantly higher than that of
our data fit to LVS grown to stationary phase in CDM (R2= 0.17).
Similarly, our data best fit that of S4 grown inM8s for 12 h (R2 =
0.18), which is higher than the results for stationary phase CDM-
grown S4 (R2 = 0.10). Presumably, growth within host cells elicits
changes in Ft that are not fully recapitulated by growth in CDM
but are more closely (though not perfectly) mimicked by growth
in BHI. While comparing FCs across distinct “omics” platforms
and between different laboratories presents some limitations
(which likely lowered the observed R2-values) the over-arching
notion that BHI-Ft are more “host-adapted”-like than MHB-
Ft appears largely intact following interrogation of ∼1,000 data
points.
While the primary thrust of our proteomics approach was to
test the notion that BHI-grown Ft are more similar to infection-
derived Ft, our data also allows for reasonable interpretation of
likely regulatory processes and players. In Ft, two highly similar
proteins, MglA and SspA, act in concert with FevR, a DNA-
and ppGpp-binding protein, to engage the RNA polymerase
complex and activate transcription of the MglA/SspA/FevR
regulon (which includes fevR but not mglA or sspA) in response
to elevated levels of ppGpp (Charity et al., 2007, 2009; Faron et al.,
2013; Rohlfing andDove, 2014; Ramsey et al., 2015). Themajority
of the FevR regulon have been shown to be up-regulated in one or
more infection models, necessary for virulence (Baron and Nano,
1998; Santic et al., 2005, 2007; Brotcke et al., 2006; Tempel et al.,
2006; Su et al., 2007; Bonquist et al., 2008; Sammons-Jackson
et al., 2008; Barker et al., 2009; Buchan et al., 2009; Dean et al.,
2009; Schmerk et al., 2009; Ahlund et al., 2010; McCaffrey et al.,
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2010; Broms et al., 2011, 2012a; Straskova et al., 2012; Robertson
et al., 2013, 2014), and, as shown here, are more abundant in
BHI-Ft (Table 1 and Table S1). Charity et al. have used genetic
approaches to show that activation of the FevR regulon requires
ppGpp generated by the activity of RelA and/or SpoT (Charity
et al., 2009). Dean and Faron have used serine hydroxamate to
induce amino acid starvation (Dean et al., 2009; Faron et al.,
2013) and observed that this starvation causes ppGpp levels to
rise by 2- to 3-fold with a corresponding 2- to 3-fold increase in
iglA promoter activity (Faron et al., 2013). Consistent with the
impact of serine hydroxamate, we found the absence of casamino
acids induced an average FPI protein induction of 2.2-fold and
a 2.6 induction of FevR (Table 1). These values are lower than
the full FPI induction reported for Ft grown in M8 for 8 h
(ave-FPI 4.6, FevR 6.9) and what we observed between BHI- and
MHB- grown Ft (ave FPI-5.3, FevR 5.0). These data suggest that
while amino acid limitation alone can induce the FevR regulon
2- to 3-fold, additional, possibly nutritional, signals contribute
to full FPI induction. Severe nutrient starvation and induction
of the stringent starvation response (mediated by RelA/SpoT
and ppGpp) results in decreased abundance of ribosomes. Of
the 47 ribosomal proteins for which we had robust FC data, 24
were statistically less abundant in BHI-Ft compared to MHB-
Ft (Table 1 and Table S2) Among these 47 proteins, 8 were
reduced in BHI compared to BCA; 12 and 32 are reportedly
reduced after 4 and 8 h respectively of growth in M8. Thus in
our data, as well as that of Bent for LVS (Bent et al., 2013) and
Lenco for LVS and S4 (Lenco et al., 2009), FPI induction appears
to correlate with ribosomal protein reduction. Intriguingly,
siderophore and pantheonate synthesis proteins are elevated in
BHI-Ft compared to MHB-Ft but not between BHI- and BCA-
Ft (Table 1) possibly indicating that the iron and pantheonate
present in MHB act as additional nutritional cues guiding the
stringent starvation response. Up regulation of these genes in
vivo and their contributions to virulence have been reported
previously (Deng et al., 2006; Sullivan et al., 2006; Lenco et al.,
2007, 2009; Ramakrishnan et al., 2008; Wehrly et al., 2009; Bent
et al., 2013; Miller et al., 2013; Thomas-Charles et al., 2013).
In the course of our analysis we also noted media-dependent
changes in protein abundance that mirror changes observed
during infection, but for proteins that have not been shown
to be dependent on the major regulatory players such as
MglA/SspA/FevR, or PmrA. Such proteins include the 12
FPI co-regulated proteins such as Dgt (FTL1503) identified
by Lenco et al. (2009) as well as several proteins that are
repressed by growth in BHI and mammalian cells such as
GuaB (FTL1478) and MetK (FTL1739) (Table 1 and Table
S1). The regulatory mechanisms governing expression of these
MglA/SspA/FevR/PmrA-independant proteins, many of which
appear to be growth phase insensitive (Lenco et al., 2009), remain
to be elucidated. Another group of proteins worth noting are
those that have been shown to be up-regulated during infection
but were not up-regulated in BHI-Ft. The primary examples
of this are several ATP synthases (FTL1794-1798) and TCA
enzymes (FTL1783-1786) which we detected as media-non-
responsive but have been shown in LVS and S4 to be down-
regulated during infection of cells and mice respectively (Twine
et al., 2006a; Bent et al., 2013). Thus, BHI-Ft are good, but not
perfect, mimics of host-adapted Ft.
Given the differences in protein abundance, it is not surprising
that host-adapted Ft have an initial growth advantage in vivo that
manifests as a slightly shorter MST of naïve animals infected with
BHI-Ft (Hazlett et al., 2008; Zarrella et al., 2011). Our finding
that these differences in apparent virulence are magnified in the
context of pre-existing specific immunity further supports the
notion that the growth status of Ft is an important factor to be
considered in tularemia research. For example, in three separate
experiments, challenge of LVS-vaccinated mice with MHB-Ft S4
revealed survival rates of 100, 100, and 70%; the corresponding
survival rates for mice challenged with BHI-Ft S4 in the same
experiments were 38, 44, and 33%. Clearly, the status of a Ft
challenge inoculum at the time of administration can have a
profound impact on experimental outcomes in tularemia vaccine
research.
At this time, we cannot state with singular certainty why
MHB-Ft S4 appears less virulent to immunized hosts than does
BHI-Ft S4. However, we suspect that this outcome stems from
the transient, phenotypic differences between MHB- and BHI-Ft
that exist immediately upon host-challenge and prior to complete
host adaptation. Broadly speaking we can envision three inter-
related properties (reduced capsule, reduced structural integrity,
and reduced VF expression) that likely weaken a MHB-grown,
S4 challenge inoculum sufficiently to allow pre-existing specific
immunity to gain the upper hand. First, MHB-Ft LVS and
S4 have less capsular material relative to their BHI-grown
counter-parts (Zarrella et al., 2011). This capsule reduces
complement deposition, which would limit losses of challenge
bacteria to alternatively-activated complement upon entry into
the mammalian milieu (Zarrella et al., 2011). Ft capsule also
limits access of specific Ab to multiple Ft Ags (Zarrella et al.,
2011). Reduced Ab binding would have two salient outcomes: (i)
bacterial losses due to classical complement activation would be
minimized and (ii) Ab-mediated phagocytosis through activating
Fc-receptors would be reduced. This capsule also limits the
access of Ft ligands to TLR2—an activating receptor responsible
for MHB-Ft-mediated production of TH1-proinflammatory
cytokines (Zarrella et al., 2011; Singh et al., 2013). Also, we
envision that the capsule may directly or indirectly engage a
discrete “anti-inflammatory” receptor that also could diminish
elicitation of protective cytokine responses. Along these lines,
the Bosio group recently reported that exogenous, purified Ft
capsule was able to dampen M8 cytokine responses to P3C (a
synthetic TLR2 agonist) and to an inflammatory, capsule mutant
of Ft S4 (Wyatt et al., 2016). Cumulatively, given the well-
established role of capsules in promoting bacterial survival, it
seems highly likely that differences in survival of immunized
hosts would be observed between challenges with (i) bacteria
encased in abundant, pre-formed capsule (such as BHI-Ft) vs. (ii)
those entering the hostile mammalian environment without a full
protective coating of pre-made capsule (such as MHB-Ft).
The second property of MHB-Ft that may contribute to
reduced fitness in the face of pre-existing immunity is their
compromised structural integrity, which promotes rapid TH1
pro-inflammatory responses. This pro-inflammatory nature
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which makes iFt LVS a better immunogen (Kumar et al., 2016)
could also make MHB-Ft S4 a worse pathogen. Previously,
we stained early-log phase MHB- and BHI-grown Ft with a
fluorescent vital dye mix and analyzed the stained bacteria
by flow cytometry. MHB-grown cultures contained five-to-
seven times more structurally-compromised (SYTOX green
positive) Ft than did BHI-grown cultures (Singh et al., 2013).
We also found that compromised Ft induce potent cellular
responses (TNF, IL-1β, and IL-6) as first reported by Peng
et al. (2011). The SYTOX-positive MHB-Ft (∼20% of the total)
were comprised of two populations, one that was moderately
stained (fluorescence intensities of 101–102) and one that stained
intensely (>103). The fluorescence intensity of the SYTOX-
positive BHI-Ft (3.5% of the total) barely exceeded 10 with
no signal greater than ∼30. Although not directly tested, we
suspect that the severely compromised Ft (present exclusively
in MHB-grown cultures) are replication-incompetent and act
simply as an inflammatory bolus within an MHB-inoculum. The
moderately-compromised MHB-Ft might be able to replicate in
a sufficiently permissive environment (such as a chocolate agar
plate or a naïve host) but are hypothesized, in the presence of
pre-existing specific immunity, to be rapidly recognized and thus
serve as additional inflammatory agonists to engage protective
recall responses. As cultures of BHI-Ft contain fewer, and less
intensely stained, SYTOX-positive bacteria, we envision that a
BHI-Ft challenge inoculum remains stealthy enough to avoid a
rapid recall response by immunized mice thereby allowing for
more productive infections.
The third property of MHB-Ft that likely promotes
susceptibility to vaccine-induced-immunity is under-expression
of virulence factors. We found that 25% of the ∼190 Ft VFs
are less abundant in MHB-Ft. When a challenge inoculum of
MHB-Ft enters the relatively permissive environment of a naïve
host, a sufficient number of viable bacteria in the inoculum
are able to replicate and host-adapt, turning on the VFs in
the process. As such, the differences in MST between naïve
(or PBS-immunized) mice challenged with MHB- and BHI-
grown Ft are small (Figures 4–6) (Hazlett et al., 2008; Zarrella
et al., 2011). In contrast, upon entry into the less-permissive
environment of a vaccinated host, the MHB-Ft inoculum
still requires time to adapt but now must do so while being
targeted by Ft-specific immune effectors. Within mammalian
hosts, one of the main functions of the bacterium’s well-studied
VFs—the FPI proteins—is to promote rapid entry into the host
cytoplasm where intact Ft replicates exponentially (Meibom
and Charbit, 2010; Ozanic et al., 2015). We anticipate that an
inoculum of MHB-Ft likely spends more time being assaulted by
extra-cellular immune effectors prior to cytoplasmic replication
than a BHI-Ft inoculum. Given a strong enough armamentarium
of immune effectors, a MHB-Ft inoculum might be unable to
mount a productive infection whereas a BHI-Ft inoculum is less
susceptible to, and spends less time dealing with, these effectors
resulting in more productive infections.
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